We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Crescita Therapeutics Inc | TSX:CTX | Toronto | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.43 | 0.42 | 0.44 | 0.44 | 0.43 | 0.44 | 2,200 | 20:59:59 |
Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its 2022 Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Québec. The detailed results of the votes received by proxy are as follows:
Election of Directors
Director Nominees
NUMBER OF SHARES
PERCENTAGE OF VOTES CAST
FOR
WITHHELD
FOR
WITHHELD
Daniel N. Chicoine
4,616,653
148,815
96.9%
3.1%
David A. Copeland
4,378,536
386,932
91.9%
8.1%
Anthony E. Dobranowski
4,363,268
402,200
91.6%
8.4%
John C. London
4,375,612
389,856
91.8%
8.2%
Thomas Schlader
4,692,345
73,123
98.5%
1.5%
Deborah Shannon-Trudeau
4,705,132
60,336
98.7%
1.3%
Appointment of External Auditors
Outcome
NUMBER OF SHARES
PERCENTAGE OF VOTES CAST
FOR
WITHHELD
FOR
WITHHELD
Ernst & Young LLP reappointed
5,442,357
15,130
99.7%
0.3%
Approval of the Continuation of Crescita’s Shareholder Rights Plan
Outcome
NUMBER OF SHARES
PERCENTAGE OF VOTES CAST
FOR
AGAINST
FOR
AGAINST
Shareholder Rights Plan approved
4,648,487
116,981
97.5%
2.5%
About Crescita Therapeutics Inc. Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and early to commercial stage prescription products. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For further details, visit www.crescitatherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220512006074/en/
Crescita Therapeutics Investor Relations Linda Kisa, CPA, CA Email: lkisa@crescitatx.com Source: Crescita Therapeutics
1 Year Crescita Therapeutics Chart |
1 Month Crescita Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions